MannKind (NASDAQ: MNKD)‘s stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Monday. They currently have a $2.00 target price on the stock.

Zacks‘ analyst wrote, “MannKind’s third quarter 2012 net loss of $0.22 per share was narrower than the year-ago loss of $0.31 and the Zacks Consensus Estimate of a loss of $0.23. We expect investor focus to remain on the fate of diabetes candidate, Afrezza, which received a second CRL from the FDA in January 2011. The FDA asked the company to conduct two additional trials with Afrezza. Management expects to complete the trials in the second quarter of 2013. Positive results would allow MannKind to file a new drug application by the third quarter of 2013. MannKind recently raised funds through an underwritten public offering. We remain Neutral on the stock. We prefer to remain on the sidelines until we see data from the two ongoing studies. “

Shares of MannKind traded up 1.01% during mid-day trading on Monday, hitting $2.00. MannKind has a 52 week low of $1.57 and a 52 week high of $3.48. The company’s market cap is $381.1 million.

MannKind last announced its earnings results on Thursday, November 1st. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. On average, analysts predict that MannKind will post $-0.89 earnings per share for the current fiscal year.

A number of other firms have also recently commented on MNKD. Analysts at Bank of America upgraded shares of MannKind from a “neutral” rating to a “buy” rating in a research note to investors on Monday. They now have a $3.00 price target on the stock. Separately, analysts at JPMorgan Chase upgraded shares of MannKind from an “underweight” rating to a “neutral” rating in a research note to investors on Friday. Finally, analysts at JMP Securities upgraded shares of MannKind from a “market perform” rating to a “market outperform” rating in a research note to investors on Friday, August 10th.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.

To view Zacks’ full report, visit www.zacks.com

http://www.dailypolitical.com/finance/stock-market/mannkind-stock-rating-reaffirmed-by-zacks-mnkd.htm